Treatment resistance of solid tumors: Role of hypoxia and anemia

Medical Oncology

Volumn 18, Issue 4, 2001, Pages 243-259

  Vaupel, Peter ^b   Thews, Oliver ^b   Hoeckel, Michael ^a  

^a UNIVERSITY OF LEIPZIG   (Germany)

^b JOHANNES GUTENBERG UNIVERSITY   (Germany)

Author keywords

Anemia; Chemotherapy; Malignant progression; Radiotherapy; Therapeutic resistance; Tumor hypoxia; Tumor oxygenation

Indexed keywords

ALKYLATING AGENT; AMINOLEVULINIC ACID; ANTINEOPLASTIC AGENT; BLEOMYCIN; CARBOPLATIN; CYCLOPHOSPHAMIDE; CYTOKINE; CYTOTOXIC AGENT; DOXORUBICIN; GAMMA INTERFERON; HEMATOPORPHYRIN DERIVATIVE; HEMOGLOBIN; PHOTOSENSITIZING AGENT; PLATINUM DERIVATIVE; PRODRUG; PROTEOME; TUMOR NECROSIS FACTOR ALPHA;

ANEMIA; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER STAGING; CLONE; DIFFUSION; GENOME; HEMOGLOBIN DETERMINATION; HUMAN; HYPOXIA; IONIZING RADIATION; MALIGNANT TRANSFORMATION; OXYGENATION; PATHOGENESIS; PHOTODYNAMIC THERAPY; PRIORITY JOURNAL; PROGNOSIS; REVIEW; SOLID TUMOR; TUMOR VASCULARIZATION;

ANEMIA; ANIMALS; ANTINEOPLASTIC AGENTS; CELL HYPOXIA; DISEASE PROGRESSION; HEMOGLOBINS; HUMANS; MICROCIRCULATION; NEOPLASMS; OXYGEN CONSUMPTION; PHOTOCHEMOTHERAPY; PROGNOSIS; RADIOTHERAPY; TREATMENT FAILURE;

EID: 0035677961     PISSN: 13570560     EISSN: None     Source Type: Journal    
DOI: 10.1385/MO:18:4:243     Document Type: Review

References (110)

1. 2 tension measurements
2. 2 tension measurements
3. Tumor hypoxia: Definitions and current clinical, biological and molecular aspects
4. 2 predicts survival in advanced cancer of the uterine cervix
5. Association between tumor hypoxia and malignant progression in advanced cancer of the uterine cervix
6. Hypoxic cervical cancers with low apoptotic index are highly aggressive
7. Tumour hypoxia and vascular density as predictors of metastasis in squamous cell carcinoma of the uterine cervix
8. Oxygenation predicts radiation response and survival in patients with cervix cancer
9. 2-measurements as predictive assay in the treatment of carcinoma of the uterine cervix
10. Treatment outcome in advanced squamous cell carcinoma of the uterine cervix: Relationships to pretreatment tumor oxygenation and vascularization
11. Pretreatment oxygenation predicts radiation response in advanced squamous cell carcinoma of the head and neck
12. Tumor hypoxia adversely affects the prognosis of carcinoma of the head and neck
13. Influence of the hypoxic subvolume on the survival of patients with head and neck cancer
14. A confirmatory prognostic study on oxygenation status and loco-regional control in advanced head and neck squamous cell carcinoma treated by radiation therapy
15. Tumor oxygenation predicts for the likelihood of distant metastases in human soft tissue sarcoma
16. 2 distribution and bioreductive enzymes in human malignant brain tumors
17. Polarographic measurements of oxygen tension in human glioma and surrounding peritumoural brain tissue
18. Hypoxic regions exist in human prostate carcinoma
19. Increasing levels of hypoxia in prostate carcinoma correlate significantly with increasing clinical stage and patient age
20. Oxygen tension in primary gynaecological tumours: The influence of carbon dioxide concentration
21. Changes in tumor oxygen tension during radiotherapy of uterine cervical cancer: Relationships to changes in vascular density, cell density, and frequency of mitosis and apoptosis
22. Oxygenation of cervical cancers during radiotherapy and radiotherapy + cis-retinoic acid/interferon
23. Severe anemia is associated with poor tumor oxygenation in head and neck squamous cell carcinomas
24. Intratumoral oxygen tension in metastatic melanoma
25. Oxygenation of squamous cell carcinoma of the head and neck: Comparison of primary tumors, neck node metastases, and normal tissue
26. Durchblutung und oxygenierungsstatus von kopf-hals-tumoren
27. Tumor hypoxia, p53, and prognosis in cervical cancers
28. Invasive oxygen measurements and pimonidazole labeling in human cervix carcinoma
29. Hypoxia in human intraperitoneal and extremity sarcomas
30. Hypoxia in human soft tissue sarcomas: Adverse impact on survival and no association with p53 mutations
31. Oxgenation status of malignant tumors: Pathogenesis of hypoxia and significance for tumor therapy
32. Hypoxie beim zervixkarzinom: Pathogenese, charakterisierung und biologische/klinische konsequenzen
33. Blood flow, oxygen and nutrient supply, and metabolic microenvironment of human tumors: A review
34. Blood flow, oxygenation, tissue pH distribution and bioenergetic status of tumors
35. Intra- and intertumor heterogeneity in blood perfusion of human cervical cancer before treatment and after radiotherapy
36. Use of recombinant human erythropoietin as an antianemic and performance enhancing drug
37. Recombinant human erythropoietin in the treatment of cancer-related or chemotherapy-induced anaemia in patients with solid tumors
38. Biological basis of anemia
39. Anemia in cancer patients
40. Chemotherapy-induced anemia in adults: Incidence and treatment
41. Impact of anemia on the oxygenation status of tumors: A theoretical study
42. Blood flow, oxygenation, and bioenergetic status of tumors after erythropoietin treatment in normal and anemic rats
43. Tumor oxygenation in anemic rats: Effects of erythropoietin treatment versus red blood cell transfusion
44. Oxygenation of human tumors: The Mainz experience
45. Tumour hypoxia and anaemia: Implications for the outcome of radiotherapy and chemotherapy
46. Human tumor oxygenation: The Duke University Medical Center experience
47. Oxygenation of human tumors: The Munich/Halle experience
48. Keynote address: The influence of microenvironmental factors on the activity of radiation and drugs
49. The influence of microenvironmental factors during cancer therapy
50. Hypoxia and drug resistance
51. Physiologic mechanisms of therapeutic resistance
52. The influence of tumor blood flow and microenvironmental factors on the efficacy of radiation, drugs and localized hyperthermia
53. Therapeutic significance of microenvironmental factors
54. The concentration of oxygen dissolved in tissues at the time of irradiation as a factor in radiotherapy
55. The influence of anemia on the results of radiotherapy in carcinoma of the cervix
56. The significance of anemia in clinical radiation therapy
57. The impact of blood hemoglobin content on the outcome of radiotherapy. The Freiburg experience
58. Erythropoietin for patients undergoing radiotherapy: The Freiburg experience
59. Significance of hemoglobin concentration for treatment outcome
60. Tumor hypoxia and anemia: Impact on the efficacy of radiation therapy
61. Blood hemoglobin level may affect radiosensitivity - Preliminary results on acutely reacting normal tissues
62. Anemia is associated with lower local-regional control and survival after radiation therapy for head and neck cancer: A prospective study
63. Pretreatment anaemia alters outcome in early squamous cell carcinoma of the larynx treated by radical radiotherapy
64. Prognostic value of hemoglobin concentrations and blood transfusions in advanced carcinoma of the cervix treated by radiation therapy: Results of a retrospective study of 386 patients
65. Prognostic impact of total tumor volume and hemoglobin concentration on the outcome of patients with advanced head and neck cancer after concomitant boost radiochemotherapy
66. The effect of hemoglobin level on radiotherapy outcomes: The Canadian experience
67. Impact of hemoglobin level and use of recombinant erythropoietin on efficacy of preoperative chemoradiation therapy for squamous cell carcinoma of the oral cavity and oropharynx
68. Prognostischer stellenwert des hämoglobinwertes vor primärer radiochemotherapy von kopf-hals-karzinomen
69. Anemia is associated with decreased local control of surgically treated squamous cell carcinomas of the glottic larynx
70. Enhanced radiosensitivity in experimental tumours following erythropoietin treatment of chemotherapy-induced anaemia
71. Modulation of tumor oxygenation and radiosensitivity by erythropoietin
72. Clinical trial experience using erythropoietin during radiation therapy
73. Classification of antineoplastic treatments by their differential toxicity toward putative oxygenated and hypoxic tumor subpopulations in vivo in the FSall murine fibrosarcoma
74. A role for the human DNA-repair enzyme HAP1 in cellular-protection against DNA-damaging agents and hypoxic stress
75. Antineoplastic agents
76. Hypoxia-induced drug resistance: Comparison to P-glycoprotein-associated drug resistance
77. Apoptosis and cancer chemotherapy
78. Erythropoietin restores the anemia-induced reduction in cyclophosphamide cytotoxicity in rat tumors
79. Effects of recombinant human erythropoietin on the antitumor effect of cisplatin in SCID mice bearing human ovarian cancer: A possible oxygen effect
80. Tumor hypoxia, reoxygenation and oxygenation strategies: Possible role in photodynamic therapy
81. Relationship of tumor hypoxia and response to photodynamic treatment in an experimental mouse tumor
82. Oxygen dependence of the photosensitizing effect of hematoporphyrin derivative in NHIK 3025 cells
83. Oxygen dependence of hematoporphyrin derivative-induced photo-inactivation of Chinese hamster cells
84. Oxygen dependency of tumor cell killing in vitro by light-activated Photofrin II
85. Tumor hypoxia and therapeutic resistance
86. Hypoxia, clonal selection, and the role of HIF-1 in tumor progression
87. HIF-1: Mediator of physiological and pathophysiological response to hypoxia
88. Hypoxia modulated gene expression: Angiogenesis, metastasis and therapeutic exploitation
89. Hypoxic stress proteins: Survival of the fittest
90. Enhanced epidermal growth factor receptor synthesis in human squamous carcinoma cells exposed to low levels of oxygen
91. Tumor hypoxia and gene expression. Implications for malignant progression and therapy
92. Genomic instability and tumor progression: Mechanistic considerations
93. Relationship of hypoxia to metastatic ability in rodent tumours
94. Hypoxia-mediated selection of cells with diminished apoptotic potential in solid tumours
95. Selection of human cervical epithelial cells that possess reduced apoptotic potential to low-oxygen conditions
96. Genetic instability induced by the tumor microenvironment
97. Microenvironment-induced cancer metastasis
98. Association between tumor hypoxia and malignant progression: The clinical evidence in cancer of the uterine cervix
99. Biological consequences of tumor hypoxia
100. Radiobiological and immunohistochemical assessment of hypoxia in human melanoma xenografts: Acute and chronic hypoxia in individual tumours
101. Dynamics of tumor oxygenation and red blood cell flux in response to inspiratory hyperoxia combined with different levels of inspiratory hypercapnia
102. Expression of hypoxia-inducible factor-1α: A novel predictive and prognostic parameter in the radiotherapy of oropharyngeal cancer
103. Targeting tumors through the HIF system
104. Suppression of tumor growth through disruption of hypoxia-inducible transcription
105. Anemia as an independent prognostic factor for survival in patients with cancer
106. The use of epoietin alfa to increase and maintain hemoglobin levels during radiotherapy
107. The impact of hemoglobin levels on treatment outcomes in patients with cancer
108. Prognostic value of hemoglobin concentrations in patients with advanced head and neck cancer treated with combined radio-chemotherapy and surgery